Pharma Marketing Network

MAY 12, 2021

Billion by 2026 with a CAGR of 37.2% Physicians and patients raise legitimate questions and concerns about the safety, effectiveness, and accessibility of telehealth. Wearable technology allows physicians to check in on the health of their patients in between physical office visits. over the Forecast Period.”.

Physicians 59

Physicians Patients Safety Marketing 59

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Sales Leads 52

Clarivate

AUGUST 27, 2024

Increased appeal for dual-energy systems: Sometimes a situation calls for RF, but physicians like the ease and efficiency of PFA. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. Abbott’s Volt should join the party in early 2026. Adagio Medical Inc.,

Marketing 52

Marketing Competition FDA Electronics 52